US VCs lead 8 AI pre-seed rounds in Europe and India

Eight AI-native startups in Europe and India have closed pre-seed rounds led by US venture capital firms, according to Sifted. The rounds range from $600K to $4.1M, covering sectors from insurance underwriting to gene-editing enzymes.

The focus here is less on the funding amounts—pre-seed rounds are small by design—and more on the investors involved. Some of these rounds were led by firms like Chingona Ventures, Activate, and Antler India. This raises questions about whether this represents a broader change in how early-stage funding is allocated, particularly in markets outside the US.

One example is a startup that raised $4.1M for AI-driven commercial insurance underwriting. The round was led by a US-based fund, despite the company operating in a sector where data and regulatory landscapes differ by region. This could suggest an interest in scaling beyond local markets or targeting specific regional opportunities.

Another case involves a Bengaluru-based startup that raised $1.9M for AI-driven gene-editing enzymes. The round was co-led by a US biotech-focused fund, which might indicate confidence in the startup’s ability to compete globally, though the specifics of that strategy remain unclear.

Not all rounds followed this pattern. A London startup building an AI human insight platform raised £1M led by a UK fund, while an AI co-creation platform secured $600K with an Indian fund as the lead. This variation suggests that while some US investors are taking early positions, others may still prefer local or regional backers.

The implications of this trend, if it holds, could be significant. Pre-seed funding is the earliest institutional stage, and leading such rounds often involves deeper engagement, such as board seats or influence over product direction. If US funds are increasingly taking these roles in non-US startups, it could signal a shift in how they source deals, though the long-term impact remains to be seen.

One question is whether this is a one-sided dynamic. US funds have the resources to lead early rounds abroad, but it’s unclear if European or Indian funds will similarly invest in US startups at this stage. Historically, non-US funds leading pre-seed rounds in the US have often done so under specific conditions, such as founder ties or clear regional market access. Whether this changes could shape future funding flows.

Another consideration is risk appetite. Pre-seed rounds are inherently high-risk, and leading them requires confidence in both the team and the idea. Some sectors, like insurance or biotech, may justify this risk due to large markets or regulatory barriers. Others, particularly in consumer AI, may face more skepticism, as seen in smaller rounds with local leads.

The next phase to watch is follow-on funding. Pre-seed rounds are just the beginning, and the real test will be whether these startups can secure Series A funding. If US funds continue to play an active role at that stage, it could confirm a lasting change in early-stage investment strategies. If not, it may simply reflect a short-term experiment.

For founders, this trend could present new opportunities. If US funds are open to leading pre-seed rounds outside their home market, it may expand access to capital. For investors, it highlights the global nature of AI deal flow, though the ultimate returns remain uncertain. The broader question is whether this marks a lasting shift or a temporary adjustment in how early-stage funding is allocated.

Sources: sifted.eu